In vivo RIBE significantly reduce human long-term hematopoietic reconstitution and clonogenic ability. (A) Experimental diagram of in vivo RIBE model. (B) Mean human cell engraftment level in peripheral blood (PB) at different time points after transplantation. (C) Representative flow plots of human hematopoietic cell engraftment in the bone marrow (BM) 20 weeks after transplantation (RIBE vs control [Ctrl]: 14.19% ± 3.809% vs 38.70% ± 7.168%, P = .009). (D) Percentage of human cell engraftment in the BM of recipients. (E-F) Frequency of human CD34⁺CD38⁻ (E) and CD34⁺CD38⁺ (F) cells in the BM of recipients. (G-H) Lineage differentiation potential (G) and frequency (H) of human CD45⁻CD235a⁺ cells in the BM of recipients; n = 10-11 per group (B-H). (I-J) Percentage of human cell engraftment (I) and lineage differentiation potential (J) of the secondary mice (RIBE vs Ctrl: 0.19% ± 0.028% vs 6.29% ± 2.586%, P = .041; n = 9-11 per group). (K) Frequency of human hematopoietic cells in the recipients measured by LDA (n = 7-11 per group). (L) Number of hematopoietic colonies formed by hCD34⁺ cells in each group (n = 5 per group) (3 independent experiments; *P < .05; **P < .01; ***P < .001).